Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1629140 | 1.00 | TTR (0.43) | TTRMEN1KMT2A | |
| SCHEMBL1629107 | 1.00 | TTR (0.43) | TTRMEN1KMT2A | |
| SCHEMBL9861537 | 1.00 | TTR (0.43) | TTRMEN1KMT2A | |
| SCHEMBL17237526 | 0.74 | — | — | |
| SCHEMBL21977521 | 0.67 | TTR (0.32) | TTR | |
| SCHEMBL21977498 | 0.67 | TTR (0.32) | TTR | |
| SCHEMBL21977481 | 0.67 | TTR (0.32) | TTR | |
| SCHEMBL759662 | 0.67 | — | — | |
| Dioxane SCHEMBL6407595 | 0.66 | — | — | |
| Dioxane SCHEMBL9836999 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4441112-A1 | METHOD OF UNDERWATER BONDING | Henkel AG & Co. KGaA (DE) | 2024-10-09 | — | — | EP | disclosed |
| US-12030971-B2 | Two-part cyanoacrylate curable adhesive system | HENKEL AG & CO. KGAA (DE) | 2024-07-09 | — | — | US | disclosed |
| US-20230365836-A1 | CYANOACRYLATE COMPOSITIONS | HENKEL AG & CO KGAA (DE) | 2023-11-16 | — | — | US | disclosed |
| US-11725119-B2 | Cyanoacrylate compositions | HENKEL AG & CO. KGAA (DE) | 2023-08-15 | — | — | US | disclosed |
| EP-4211141-A1 | SILACROWN ETHERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THERAPEUTIC APPLICATIONS THEREOF | Arkles, Barry, C. (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2023099777-A1 | METHOD OF UNDERWATER BONDING | Henkel IP & Holding GmbH (DE) | 2023-06-08 | — | — | WO | disclosed |
| US-20230135462-A1 | CYANOACRYLATE COMPOSITIONS | HENKEL AG & CO KGAA (DE) | 2023-05-04 | — | — | US | disclosed |
| CN-115799614-A | Secondary battery | 珠海冠宇电池股份有限公司 | 2023-03-14 | — | — | CN | disclosed |
| EP-4061865-A1 | TWO COMPONENT (2K) CURABLE COMPOSITION | Henkel AG & Co. KGaA (DE) | 2022-09-28 | — | — | EP | disclosed |
| WO-2022055745-A1 | SILACROWN ETHERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THERAPEUTIC APPLICATIONS THEREOF | ARKLES BARRY C (US) | 2022-03-17 | — | — | WO | disclosed |
| US-8192731-B2 | Thickened cyanoacrylate compositions | LOCTITE (R&D) LIMITED (IE) | 2012-06-05 | — | — | US | disclosed |
| US-20120085492-A1 | CYANOACRYLATE COMPOSITIONS | LOCTITE(R&D) LIMITED (IE) | 2012-04-12 | — | — | US | disclosed |
| US-20100210788-A1 | ELECTRON DEFICIENT OLEFINS | LOCTITE (R&D) LIMITED (IE) | 2010-08-19 | — | — | US | disclosed |
| US-20100199888-A1 | ACTIVATED METHYLENE REAGENTS AND CURABLE COMPOSITIONS PREPARED THEREFROM | LOCTITE (R&D) LIMITED (IE) | 2010-08-12 | — | — | US | disclosed |
| US-7687561-B1 | Toughened cyanoacrylate compositions | LOCTITE (R&D) LIMITED (IE) | 2010-03-30 | — | — | US | disclosed |
| US-20090298969-A1 | CYANOACRYLATE COMPOSITIONS CONTAINING DISPERSIONS OF CORE SHELL RUBBERS IN (METH)ACRYLATES | HENKEL CORPORATION (US) | 2009-12-03 | — | — | US | disclosed |
| US-20080314519-A1 | Toughened Cyanoacrylate Compositions | HENKEL CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| US-7390851-B1 | Toughened cyanoacrylate compositions | LOCTITE (R&D) LIMITED (IE) | 2008-06-24 | — | — | US | disclosed |
| US-20070137784-A1 | Cyanoacrylate composite forming system | LOCTITE (R&D) LIMITED | 2007-06-21 | — | — | US | disclosed |
| US-20070092481-A1 | Thickened cyanoacrylate compositions | LOCTITE (R&D) LIMITED | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100199888-A1 | ACTIVATED METHYLENE REAGENTS AND CURABLE COMPOSITIONS PREPARED THEREFROM | NOTUM, WASF2, BHMT2 | TTR 4541/4885MEN1 2833/4885KMT2A 1499/4885 |
| US-20100210788-A1 | ELECTRON DEFICIENT OLEFINS | MAL2, IDH2, SLC25A11 | TTR 4268/4885MEN1 308/4885KMT2A 2492/4885 |
| US-20070092481-A1 | Thickened cyanoacrylate compositions | MMAB, MCM4, MCM3 | TTR 2239/4885MEN1 2837/4885KMT2A 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.